A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Public ClinicalTrials.gov record NCT04155424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to \< 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
Study identification
- NCT ID
- NCT04155424
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 5 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 14, 2020 (Actual)
- Primary completion
- Jul 31, 2023 (Actual)
- Completion
- Jul 31, 2023 (Actual)
- Last update posted
- Sep 25, 2024
2020 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | San Francisco | California | 94016 | — |
| Clinical Trial Site | Washington D.C. | District of Columbia | 20001 | — |
| Clinical Trial Site | Miami | Florida | 33101 | — |
| Clinical Trial Site | Atlanta | Georgia | 30301 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Clinical Trial Site | Rockville | Maryland | 20847 | — |
| Clinical Trial Site | Boston | Massachusetts | 02101 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | St Louis | Missouri | 63130 | — |
| Research Site | Hackensack | New Jersey | 07601 | — |
| Research Site | New Brunswick | New Jersey | 08901 | — |
| Research Site | New York | New York | 10016 | — |
| Clinical Trial Site | Chapel Hill | North Carolina | 27514 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19019 | — |
| Research Site | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04155424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04155424 live on ClinicalTrials.gov.